Research advances of bispecific antibody drugs in tumor therapy

VernacularTitle:双特异性抗体药物在肿瘤治疗领域的研究进展
Author: Yali YUE ¹ ; Jun YIN ; Xiangdong GAO ; Wenbing YAO
Author Information

1. 中国药科大学江苏省生物药物成药性研究重点实验室；生命科学与技术学院
Publication Type:Journal Article
Keywords: bispecific antibody; antitumor; catumaxomab; blinatumomab; progress
From: Journal of China Pharmaceutical University 2019;50(3):289-298
CountryChina
Language:Chinese
Abstract: Tumor immunotherapy is currently the new direction for the treatment of cancer. Bispecific antibody can bind two different antigens, so the development prospect in the field of tumor treatment is very attractive. The most compelling trifunctional antibody and bispecific T-cell engager in bispecific antibodies have been marketed separately, with representative drugs as catumaxomab and blinatumomab, respectively. So far, nearly 100 antitumor bispecific antibody drugs are undergoing clinical trials and in-depth understanding of their mechanisms of action will provide more powerful solutions for cancer treatment. This review summarizes the progress of catumaxomab, blinatumomab and current highly promising bispecific antibody drugs, for the further development and application of tumor therapy.